Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTE NASDAQ:COGT NASDAQ:RGC NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$145.09-1.3%$150.71$56.10▼$200.00$5.82B-1.24195,478 shs214,856 shsCOGTCogent Biosciences$36.31+1.3%$34.40$6.94▼$43.73$6.20B0.342.14 million shs4.05 million shsRGCRegencell Bioscience$11.08+5.4%$24.88$9.39▼$69.00$5.48B1.66281,086 shs256,857 shsVIRVir Biotechnology$10.16+6.2%$9.44$4.16▼$11.66$1.71B1.652.73 million shs2.53 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+0.65%+1.96%+7.12%-2.49%+143.17%COGTCogent Biosciences+3.76%+8.05%+9.70%+2.52%+395.71%RGCRegencell Bioscience-12.49%-38.50%-59.26%-56.96%-72.35%VIRVir Biotechnology+4.48%+11.15%+4.13%+11.67%+82.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$145.09-1.3%$150.71$56.10▼$200.00$5.82B-1.24195,478 shs214,856 shsCOGTCogent Biosciences$36.31+1.3%$34.40$6.94▼$43.73$6.20B0.342.14 million shs4.05 million shsRGCRegencell Bioscience$11.08+5.4%$24.88$9.39▼$69.00$5.48B1.66281,086 shs256,857 shsVIRVir Biotechnology$10.16+6.2%$9.44$4.16▼$11.66$1.71B1.652.73 million shs2.53 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+0.65%+1.96%+7.12%-2.49%+143.17%COGTCogent Biosciences+3.76%+8.05%+9.70%+2.52%+395.71%RGCRegencell Bioscience-12.49%-38.50%-59.26%-56.96%-72.35%VIRVir Biotechnology+4.48%+11.15%+4.13%+11.67%+82.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 2.63Moderate Buy$203.0039.91% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.7320.43% UpsideRGCRegencell Bioscience 1.00SellN/AN/AVIRVir Biotechnology 2.89Moderate Buy$20.88105.46% UpsideCurrent Analyst Ratings BreakdownLatest VIR, RGC, COGT, and BLTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026BLTEBelite Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.006/11/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$23.00 ➝ $27.006/3/2026VIRVir Biotechnology Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$20.00 ➝ $21.005/29/2026COGTCogent Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.005/26/2026BLTEBelite Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$223.00 ➝ $215.005/22/2026BLTEBelite Bio Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$217.005/22/2026BLTEBelite Bio BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026BLTEBelite Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.005/8/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$23.005/6/2026COGTCogent Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.004/22/2026BLTEBelite Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.00(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$20.54 per shareN/ACOGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/ARGCRegencell BioscienceN/AN/AN/AN/A$0.01 per shareN/AVIRVir Biotechnology$68.56M24.99N/AN/A$5.50 per share1.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$77.61M-$2.53N/A119.91N/AN/A-13.14%-12.88%8/10/2026 (Estimated)COGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)RGCRegencell Bioscience-$3.58MN/AN/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology-$437.99M-$3.13N/AN/AN/A-638.88%-53.31%-41.76%8/5/2026 (Estimated)Latest VIR, RGC, COGT, and BLTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BLTEBelite Bio-$0.60-$0.34+$0.26-$0.68N/AN/A5/8/2026Q1 2026RGCRegencell BioscienceN/A-$0.0050N/A-$0.0050N/AN/A5/6/2026Q1 2026VIRVir Biotechnology-$0.01-$0.85-$0.84-$0.85$55.49 million($0.03) million5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A33.7133.71COGTCogent Biosciences0.4115.1415.14RGCRegencell BioscienceN/A1.41N/AVIRVir BiotechnologyN/A7.117.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%COGTCogent BiosciencesN/ARGCRegencell Bioscience0.13%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%COGTCogent Biosciences6.59%RGCRegencell BioscienceN/AVIRVir Biotechnology2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1040.08 million34.76 millionNot OptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionableRGCRegencell Bioscience10494.49 millionN/AN/AVIRVir Biotechnology580168.65 million163.76 millionOptionableVIR, RGC, COGT, and BLTE HeadlinesRecent News About These CompaniesVir Biotechnology (NASDAQ:VIR) Draws Attention Amid Pipeline FocusJune 22 at 1:29 PM | kalkinemedia.comKVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 22 at 2:18 AM | marketbeat.comMorgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00June 11, 2026 | marketbeat.comVir Biotechnology Adds Timothy Coughlin to Board, Audit ChairJune 10, 2026 | tipranks.comVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of DirectorsJune 10, 2026 | businesswire.comWINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIRJune 10, 2026 | marketbeat.comBarclays Sticks to Its Buy Rating for Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | insidermonkey.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | finance.yahoo.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $21.00June 3, 2026 | marketbeat.comInsider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 3,200 Shares of StockJune 3, 2026 | insidertrades.comVir Biotechnology, Inc. (VIR) Presents at EASL Congress 2026 - SlideshowMay 30, 2026 | seekingalpha.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by AnalystsMay 28, 2026 | marketbeat.comSF Biotech Boss Slashes Labs, Bets Big On Cancer In High-Stakes Vir MakeoverMay 27, 2026 | hoodline.comHUBS Group AG Purchases 203,203 Shares of Vir Biotechnology, Inc. $VIRMay 27, 2026 | marketbeat.comHow SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment StoryMay 25, 2026 | finance.yahoo.comWhy a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallyMay 23, 2026 | aol.comAVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL ...May 19, 2026 | finance.yahoo.comVir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 MillionMay 19, 2026 | finance.yahoo.comVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026May 18, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 20263 Rate-Ready Stocks for the New Fed Chair’s First Big TestBy Chris Markoch | June 16, 2026VIR, RGC, COGT, and BLTE Company DescriptionsBelite Bio NASDAQ:BLTE$145.09 -1.98 (-1.35%) As of 04:00 PM EasternBelite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Cogent Biosciences NASDAQ:COGT$36.31 +0.47 (+1.31%) As of 04:00 PM EasternCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Regencell Bioscience NASDAQ:RGC$11.08 +0.57 (+5.42%) As of 04:00 PM EasternRegencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.Vir Biotechnology NASDAQ:VIR$10.16 +0.59 (+6.17%) As of 04:00 PM EasternVir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
